Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
127M
-
Number of holders
-
73
-
Total 13F shares, excl. options
-
44.5M
-
Shares change
-
-1.1M
-
Total reported value, excl. options
-
$123M
-
Value change
-
-$833K
-
Put/Call ratio
-
439.32
-
Number of buys
-
31
-
Number of sells
-
-27
-
Price
-
$2.77
Significant Holders of Nautilus Biotechnology, Inc. - Common Stock, $0.0001 par value per share (NAUT) as of Q1 2023
88 filings reported holding NAUT - Nautilus Biotechnology, Inc. - Common Stock, $0.0001 par value per share as of Q1 2023.
Nautilus Biotechnology, Inc. - Common Stock, $0.0001 par value per share (NAUT) has 73 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 44.5M shares
of 127M outstanding shares and own 35.07% of the company stock.
Largest 10 shareholders include PERCEPTIVE ADVISORS LLC (9.11M shares), Cercano Management LLC (7.17M shares), Madrona Venture Group, LLC (6.02M shares), BlackRock Inc. (3.3M shares), VANGUARD GROUP INC (2.84M shares), Comprehensive Financial Management LLC (2.22M shares), Bain Capital Life Sciences Investors, LLC (2M shares), Tikvah Management LLC (1.49M shares), AMAZON COM INC (1.46M shares), and ArchPoint Investors (1.45M shares).
This table shows the top 73 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.